This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves - Summary - MDSpire

This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward

  • May 26, 2026

  • 9 min

Share

Objective:

To summarize recent developments in biopharmaceuticals, including clinical trial results and regulatory updates.

Key Findings:
  • Sac-TMT met primary endpoints in endometrial cancer.
  • MB097 showed safety and efficacy in advanced melanoma.
  • Ligufalimab demonstrated a survival signal in AML.
  • Regeneron's melanoma trial did not meet primary endpoint.
  • Dual-pressure CHO system improved antibody productivity.
  • Bispecific antibody architecture impacts manufacturability.
  • High-concentration mAbs present new manufacturing challenges.
  • FDA guidance aims to enhance pregnancy safety data collection.
Interpretation:

Limitations:
Conclusion:

Original Source(s)

This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

  • May 26, 2026

Related Content

When Insight Meets Urgency in Cell and Gene Therapy

Balancing deep biological insight with the realities of development is now central to progress in advanced medicine

New Mammography Screening Guidance: Clinical Considerations for Risk-Based Care

New guidance from the American College of Physicians (ACP) recommends biennial mammography screening for average-risk women ages 50 to 74.

  • by

  • May 26, 2026

  • 5 min
Beyond Nodule Detection: AI, Chest CT, and a Vision for Population Health

Lung cancer resulted in 1.8 million deaths globally in 2022 and remains the leading cause of cancer-related mortality worldwide. Low-dose CT screening has been shown to reduce lung cancer mortality, a...